Inhibitory activities of Cystoseira crinita sulfated polysaccharide on key enzymes related to diabetes and hypertension: in vitro and animal study
Inhibitory activities of Cystoseira crinita sulfated polysaccharide on key enzymes related to diabetes and hypertension: in vitro and animal study
复制标题
DOI：
10.1080/13813455.2016.1232737
复制
发表时间：
2017-02-01
影响因子：
3
通讯作者：
Belghith, Karima
中科院分区：
文献类型：
--
作者：
Ben Gara, Amel;Kolsi, Rihab Ben Abdallah;Belghith, Karima
本研究通过体外实验和糖尿病大鼠模型，研究了长吻囊塞藻硫酸多糖（CCSP）对糖尿病相关关键酶活性的影响。CCSP对胰淀粉酶和血管紧张素转换酶活性的抑制作用分别为IC_（50）= 39.16 μ g/ml和IC_（50）= 58.35 μ g/ml。在糖尿病大鼠中，与未治疗的糖尿病大鼠相比，CCSP的给药使血清、胰腺和肠中α-淀粉酶的活性分别降低了23%、44.38%和45%。此外，对存活的糖尿病大鼠施用CCSP保护胰腺细胞免于死亡和损伤，这导致胰岛素水平。淀粉酶的减少和胰岛素水平的增加导致葡萄糖速率降低56%，与未经处理的糖尿病大鼠相比。口服葡萄糖耐量试验（OGTT）证实了CCSP对β-淀粉酶活性的抑制作用和降血糖作用。此外，存活的糖尿病大鼠接受CCSP给药后，血脂正常化，刺激抗氧化能力，并预防肝肾毒性，肝肾毒性的血清指数降低证明了这一点，并通过组织学分析得到证实。本研究中呈现的总体结果表明，将CCSP给予糖尿病大鼠可使其成为作为治疗高血糖症、高脂血症和肝肾功能障碍的药理学试剂的工业应用的潜在强有力候选物。
The present study investigated the effect of the Cystoseira crinita sulfated polysaccharide (CCSP) on key enzymes activities related to diabetes in vitro and in diabetic rats. We found that CCSP inhibited pancreatic -amylase with IC50 = 39.16g/ml and angiotensin I-converting enzyme (ACE) activity with IC50=58.35g/ml in vitro. In diabetic rats, the administration of CCSP reduced the activity of -amylase in serum, pancreas, and intestine by 23%, 44.38%, and 45%, respectively as compared to untreated diabetic rats. Moreover, the administration of CCSP to surviving diabetic rats protects pancreas cells from death and damage, which leads to insulin levels. The decrease in -amylase and the increase in insulin level lead to a decrease in glucose rate by 56% as compared to untreated diabetic rats. The inhibitory action of -amylase activity and hypoglycemic effect of CCSP were confirmed by oral glucose tolerance test (OGTT). In addition, the administration of CCSP to surviving diabetic rats normalizes lipid profile, stimulates antioxidant capacity, and prevents liver-kidney toxicities, evidenced by decrease in serum indices of liver and kidney toxicity and confirmed by histological analysis. The overall findings presented in this study demonstrate that the administration of CCSP to diabetic rats can make it a potentially strong candidate for industrial application as a pharmacological agent for the treatment of hyperglycemia, hyperlipidemia, and liver-kidney dysfunctions.